This document explains the disciplinary proceedings under IMMAF’s Anti-Doping Rules concerning an Anti-Doping Rule Violation committed by Ms Aleksandra Rola and sets out consequences applied.

Background and Facts

1. IMMAF is the International Federation for Mixed Martial Arts. The IMMAF Anti-Doping Policy applies to all members and competitions, activities organised, convened, authorised or recognised by IMMAF.

2. Ms Aleksandra ROLA participated in the category Womens Strawweight of the IMMAF World Championships 2016 held in Las Vegas USA. Following the final bout on 10th July 2016, a no-notice in-competition doping control test carried out on Ms Rola, was analysed at a World Anti-Doping Agency (WADA) accredited laboratory, UCLA, in accordance with the procedures set out in the WADA International Standard for Laboratories. The analysis revealed adverse findings for the presence of the following Prohibited Substances:
a. canrenone and 7α-thiomethylspironolactone, metabolites of spironolactone, classified as Diuretics and Masking Agents (S5) on the 2016 Prohibited List of Substances and Methods, adopted by IMMAF as part of its Anti-Doping Policy.

3. Ms Rola does not have, nor has he ever held, a Therapeutic Use Exemption in respect of these substances.

4. On 10th August 2016, IMMAF issued a ‘Notification of an Adverse Analytical Finding’, relating to the commission of an Anti-Doping Rule Violation pursuant to Article 2.1 of IMMAF’s Anti-Doping Rules (Presence of Prohibited Substances). The Notification explained the facts concluding the adverse findings in the A Sample, procedures for analysis of the B Sample should these findings be disputed and consequences for admission or confirmation of an ADRV. Ms Rola was provisionally suspended from all competition from 10th August 2016.

5. Ms Rola has declined to challenge the assertion that this finding constitutes an Anti-Doping Rule Violation under the IMMAF Anti-Doping Policy and has therefore waived the B Sample analysis, thus admitting the commission of an Anti-Doping Rule Violation. This decision records the Consequences to be applied in respect of admission of that violation.

Anti-Doping Rules, Admission and Consequences
6. Ms Rola has committed a violation pursuant to Article 2.1 which provides that the Presence of a Prohibited Substance or its Metabolites or Markers in an Athlete's Sample constitutes a violation.

7. In accordance with Article 10.2, (Ineligibility for Presence, Use or Attempted Use, or Possession of a Prohibited Substance or Prohibited Method), the relevant sanction to be applied for a first offence, (subject to potential reduction or suspension pursuant to Article 10.4, 10.5, 10.6), shall be four years, where:

The Anti-Doping Rule Violation does not involve a Specified Substance (as defined by the IMMAF Prohibited List, unless the Athlete can establish the ADRV was not intentional, or the ADRV does involve a Specified Substance and IMMAF can establish that the ADRV was intentional. If either does not apply the period of ineligibility shall be two years.

8. Evidence provided on behalf of Ms Rola indicates the possibility of a medical justification for the use of this prohibited substance, suggesting that her action was not intending to cheat, however the absence of an approved, valid Therapeutic Use Exemption means that approved medical justification was not in place at the time of testing. Therefore any reduction of sanction under this clause is at IMMAF’s discretion.

9. Article 10.6.3 provides that Ms Rola may receive a reduction in the period of Ineligibility down to a minimum of two years’ if she has made a prompt admission; any reduction depends on “the seriousness of the violation and Ms Rola’s ‘degree of Fault’. Ms Rola is considered to have made a prompt admission of the Anti-Doping Rule Violation through the submission of medical information and acceded to the consequences specified by IMMAF (or is deemed to have done so in accordance with Article 7.10), waiving B Sample Analysis and accepting the result of her A Sample. IMMAF has considered the seriousness of the violation, including the fact that the
substance detected is a “specified” substance; IMMAF has grounds to exercise its discretion to reduce the period of ineligibility.

10. Consequently the period of ineligibility from competitions, activities organised, convened, authorised or recognised by IMMAF, its member organisations, of four (4) years, shall, at IMMAF’s discretion be reduced by two years.

11. Results obtained at the 2016 World Championships are disqualified, including forfeiture of all medals, points and prizes. Ms Rola’s membership of IMMAF and its national member organisations is suspended for the period of this sanction and this ineligibility to compete shall be recognised by other sports and organisations applying mutual recognition. Ms Rola has been Provisionally Suspended since the date of the Notification; in accordance with Article 10.11.12, her suspension shall commence from the date of sample collection (10 July 2016) through to midnight on 09 July 2018. During this period of ineligibility, Ms Rola shall remain subject to testing, as a condition of eligibility to return to the sport. She may return to train with a team or use the facilities of a club or other member organisation during the last two months of the period of ineligibility.

12. Ms Rola, MMAF Poland and WADA have a right of appeal against this determination or any part of it, in accordance with Article 13, to the Court of Arbitration for Sport. The time to file an appeal shall be 21 days from the receipt of this decision. This decision shall remain in place whilst under appeal. A full statement of the final issued decision shall be published, as required by Article 14.3.

13. Summary: IMMAF has issued this decision which records that
• Ms Rola has committed an Anti-Doping Rule Violation pursuant to Article 2.1,

• The period of ineligibility imposed is two years,

• Results obtained at the 2016 World Championship are disqualified.

Densign White

Chief Executive

International Mixed Martial Arts Federation

1st January 2017